Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;46(5):480-481.
doi: 10.1016/j.tips.2025.02.008. Epub 2025 Mar 24.

Suzetrigine for moderate to severe acute pain

Eun Bee Cho  1 , Chenyao Jiang  1 , Zihan Wang  2 , Ying Yu  3 , Jianxiong Jiang  4
Affiliations

Suzetrigine for moderate to severe acute pain

Eun Bee Cho et al. Trends Pharmacol Sci. 2025 May.

Abstract

Suzetrigine (VX-548), 2-pyridinecarboxamide, 4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, or 4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide, is a selective voltage-gated sodium channel NaV1.8 blocker that was recently approved by FDA as a non-opioid analgesic to treat moderate to severe acute pain. It has a molecular formula C21H20F5N3O4 and a molecular weight of 473.4 g/mol. The molecule has a chiral tetrahydrofuran core (2R,3S,4S,5R) that is conjugated to a picolinamide ring via an amide linker at position 2, a 3,4-difluoro-2-methoxyphenyl group at position 3, a methyl group at position 4, and both a trifluoromethyl group and a methyl group at position 5.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare that there are no conflicts of interest.

References

    1. Renganathan M et al. (2001) Contribution of NaV1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86, 629–640 - PubMed
    1. Jarvis MF et al. (2007) A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U. S. A. 104, 8520–8525 - PMC - PubMed
    1. Kissin I (2010) The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth. Analg. 110, 780–789 - PubMed
    1. Sinatra R (2010) Causes and consequences of inadequate management of acute pain. Pain Med. 11, 1859–1871 - PubMed
    1. Chou R et al. (2016) Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J. Pain 17, 131–157 - PubMed

LinkOut - more resources